Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14393677 | 0.87 | HPGD (0.55) | HPGDALDH1A1KMT2AACACBNAMPT | |
| SCHEMBL13328247 | 0.84 | SMN1; SMN2 (0.65) | HPGDTRPV1NAMPTPPARDNPC1 | |
| SCHEMBL25016755 | 0.83 | CYP1A2 (0.58) | KMT2ATRPV1ACACBPPARDNPC1 | |
| SCHEMBL2056358 | 0.82 | HPGD (0.64) | HPGDALDH1A1KMT2ANAMPTNPC1 | |
| SCHEMBL7445362 | 0.82 | HPGD (0.64) | HPGDALDH1A1KMT2ANAMPTLOXL2 | |
| SCHEMBL12001250 | 0.81 | ACACB (0.66) | ACACB | |
| SCHEMBL19634404 | 0.81 | LOXL2 (0.64) | HPGDALDH1A1KMT2ANAMPTLOXL2 | |
| SCHEMBL9229365 | 0.81 | ALDH1A1 (0.67) | HPGDALDH1A1KMT2ANAMPTLOXL2 | |
| SCHEMBL19465880 | 0.81 | HPGD (0.62) | HPGDALDH1A1KMT2ANAMPTLOXL2 | |
| SCHEMBL12089923 | 0.81 | HPGD (0.62) | HPGDALDH1A1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790245-B2 | Water soluble catalysts for NMR/MRI enhancement | VANDERBILT UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790245-B2 | Water soluble catalysts for NMR/MRI enhancement | VANDERBILT UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | HPGD 3387/4885ALDH1A1 1197/4885KMT2A 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.